Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study
Authors:
- for the RAID-HF (Registry Analysis of Iron Deficiency-Heart Failure) Study GroupFGfor the RAID-HF (Registry Analysis of Iron Deficiency-Heart Failure) Study Group
- Harm WienbergenHWHarm Wienbergen
- 12 July 2018
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 108 (1) , 93-100
Abstract
Introduction Iron deficiency (ID) has been recognized as a relevant comorbidity in heart failure with reduced ejection fraction (HFrEF); however, study data have shown that diagnostic and therapeutic efforts on ID are primarily performed in patients with anemia. Methods The RAID-HF registry investigated consecutive patients with ID and HFrEF in 11 heart centers in Germany and Switzerland. The present analysis focuses on 1-year follow-up data in patients with versus without anemia. Results In 505 patients with HFrEF and ID and 418 patients with HFrEF without ID 1-year follow-up was performed. Patients with ID had a higher long-term mortality compared to those without ID (19.5% vs. 13.7%, p = 0.02) and reported a lower quality of life. Only a minority of patients with ID (9.3%) received iron supplementation during long-term course, just 4.7% intravenously. Anemia was associated with an elevated mortality whereas ID versus no ID did not predict mortality in anemic patients (log-rank p = 0.78). However, in patients without anemia ID versus no ID predicted mortality (log-rank p = 0.002). In the adjusted analysis a significant interaction remained, with ID being a significant predictor of 1-year mortality in patients without anemia (HR 2.15, 95% CI 1.12–3.78), but not in anemic patients (HR 0.99, 95% CI 0.65–1.49). Conclusions RAID-HF demonstrates the impact of ID on long-term mortality and quality of life in patients with HFrEF and reveals an underuse of iron supplementation in current clinical practice. Particularly in patients without anemia the diagnosis of ID is of clinical relevance to identify patients at higher mortality risk.Keywords
Funding Information
- Vifor Pharma (DE), Vifor Pharma
This publication has 30 references indexed in Scilit:
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart FailureNew England Journal of Medicine, 2013
- Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen HerzinsuffizienzDer Kardiologe, 2013
- Health Economic Assessment of Ferric Carboxymaltose in Patients with Iron Deficiency and Chronic Heart Failure Based on the FAIR-HF Trial: An Analysis for the UKEuropean Journal of Heart Failure, 2012
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart FailureJournal of Cardiac Failure, 2011
- Iron Deficiency in Community-Dwelling US Adults With Self-Reported Heart Failure in the National Health and Nutrition Examination Survey IIICirculation: Heart Failure, 2011
- Disordered Iron Homeostasis in Chronic Heart FailureJACC, 2011
- Iron deficiency: an ominous sign in patients with systolic chronic heart failureEuropean Heart Journal, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron DeficiencyJACC, 2008